Loading clinical trials...
Loading clinical trials...
Phase I Trial of OPB-111077 in Combination With Decitabine and Venetoclax for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy
Conditions
Interventions
STAT Inhibitor OPB-111077
Decitabine
+2 more
Locations
1
United States
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Start Date
March 17, 2017
Primary Completion Date
January 18, 2024
Completion Date
March 4, 2024
Last Updated
May 15, 2025
NCT05564390
NCT03050268
NCT07320235
NCT06782542
NCT06439199
NCT05886049
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions